Jagadish Vangipurapu1, Lilian Fernandes Silva1, Teemu Kuulasmaa2, Ulf Smith3, Markku Laakso4,5. 1. Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. 2. Institute of Biomedicine, Bioinformatics Center, University of Eastern Finland, Kuopio, Finland. 3. Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland markku.laakso@uef.fi. 5. Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Abstract
OBJECTIVE: Recent studies have highlighted the significance of the microbiome in human health and disease. Changes in the metabolites produced by microbiota have been implicated in several diseases. Our objective was to identify microbiome metabolites that are associated with type 2 diabetes. RESEARCH DESIGN AND METHODS: Our study included 5,181 participants from the cross-sectional Metabolic Syndrome in Men (METSIM) study that included Finnish men (age 57 ± 7 years, BMI 26.5 ± 3.5 kg/m2) having metabolomics data available. Metabolomics analysis was performed based on fasting plasma samples. On the basis of an oral glucose tolerance test, Matsuda ISI and disposition index values were calculated as markers of insulin sensitivity and insulin secretion. A total of 4,851 participants had a 7.4-year follow-up visit, and 522 participants developed type 2 diabetes. RESULTS: Creatine, 1-palmitoleoylglycerol (16:1), urate, 2-hydroxybutyrate/2-hydroxyisobutyrate, xanthine, xanthurenate, kynurenate, 3-(4-hydroxyphenyl)lactate, 1-oleoylglycerol (18:1), 1-myristoylglycerol (14:0), dimethylglycine, and 2-hydroxyhippurate (salicylurate) were significantly associated with an increased risk of type 2 diabetes. These metabolites were associated with decreased insulin secretion or insulin sensitivity or both. Among the metabolites that were associated with a decreased risk of type 2 diabetes, 1-linoleoylglycerophosphocholine (18:2) significantly reduced the risk of type 2 diabetes. CONCLUSIONS: Several novel and previously reported microbial metabolites related to the gut microbiota were associated with an increased risk of incident type 2 diabetes, and they were also associated with decreased insulin secretion and insulin sensitivity. Microbial metabolites are important biomarkers for the risk of type 2 diabetes.
OBJECTIVE: Recent studies have highlighted the significance of the microbiome in human health and disease. Changes in the metabolites produced by microbiota have been implicated in several diseases. Our objective was to identify microbiome metabolites that are associated with type 2 diabetes. RESEARCH DESIGN AND METHODS: Our study included 5,181 participants from the cross-sectional Metabolic Syndrome in Men (METSIM) study that included Finnish men (age 57 ± 7 years, BMI 26.5 ± 3.5 kg/m2) having metabolomics data available. Metabolomics analysis was performed based on fasting plasma samples. On the basis of an oral glucose tolerance test, Matsuda ISI and disposition index values were calculated as markers of insulin sensitivity and insulin secretion. A total of 4,851 participants had a 7.4-year follow-up visit, and 522 participants developed type 2 diabetes. RESULTS: Creatine, 1-palmitoleoylglycerol (16:1), urate, 2-hydroxybutyrate/2-hydroxyisobutyrate, xanthine, xanthurenate, kynurenate, 3-(4-hydroxyphenyl)lactate, 1-oleoylglycerol (18:1), 1-myristoylglycerol (14:0), dimethylglycine, and 2-hydroxyhippurate (salicylurate) were significantly associated with an increased risk of type 2 diabetes. These metabolites were associated with decreased insulin secretion or insulin sensitivity or both. Among the metabolites that were associated with a decreased risk of type 2 diabetes, 1-linoleoylglycerophosphocholine (18:2) significantly reduced the risk of type 2 diabetes. CONCLUSIONS: Several novel and previously reported microbial metabolites related to the gut microbiota were associated with an increased risk of incident type 2 diabetes, and they were also associated with decreased insulin secretion and insulin sensitivity. Microbial metabolites are important biomarkers for the risk of type 2 diabetes.
Authors: Noha A Yousri; Karsten Suhre; Esraa Yassin; Alya Al-Shakaki; Amal Robay; Maha Elshafei; Omar Chidiac; Steven C Hunt; Ronald G Crystal; Khalid A Fakhro Journal: Diabetes Date: 2022-02-01 Impact factor: 9.461
Authors: Jin Choul Chai; Guo-Chong Chen; Bing Yu; Jiaqian Xing; Jun Li; Tasneem Khambaty; Krista M Perreira; Marisa J Perera; Denise C Vidot; Sheila F Castaneda; Elizabeth Selvin; Casey M Rebholz; Martha L Daviglus; Jianwen Cai; Linda Van Horn; Carmen R Isasi; Qi Sun; Meredith Hawkins; Xiaonan Xue; Eric Boerwinkle; Robert C Kaplan; Qibin Qi Journal: Diabetes Date: 2022-06-01 Impact factor: 9.337
Authors: Qibin Qi; Jun Li; Bing Yu; Jee-Young Moon; Jin C Chai; Jordi Merino; Jie Hu; Miguel Ruiz-Canela; Casey Rebholz; Zheng Wang; Mykhaylo Usyk; Guo-Chong Chen; Bianca C Porneala; Wenshuang Wang; Ngoc Quynh Nguyen; Elena V Feofanova; Megan L Grove; Thomas J Wang; Robert E Gerszten; Josée Dupuis; Jordi Salas-Salvadó; Wei Bao; David L Perkins; Martha L Daviglus; Bharat Thyagarajan; Jianwen Cai; Tao Wang; JoAnn E Manson; Miguel A Martínez-González; Elizabeth Selvin; Kathryn M Rexrode; Clary B Clish; Frank B Hu; James B Meigs; Rob Knight; Robert D Burk; Eric Boerwinkle; Robert C Kaplan Journal: Gut Date: 2021-06-14 Impact factor: 31.793